Coexistence of psoriasis and vitiligo in the same patient is a therapeutic challenge; several modalities have been tried with varying results. Apremilast is a PDE4 inhibitor used in psoriasis, while recent reports are highlighting its additional role in repigmentation of vitiligo. However, data are scarce, regarding its usage in the pediatric population. Narrowband ultraviolet B therapy (NB-UVB) is an effective treatment modality in both psoriasis and vitiligo and can be safely combined with apremilast. Here, we present an adolescent girl with anatomical colocalization of psoriasis and vitiligo effectively treated with combination of apremilast and NB-UVB therapy. How to cite this article: Hassanandani T, Panda M, Patro N, Kar D. Colocalization of psoriasis and vitiligo treated with apremilast and narrowband ultraviolet B combination in an adolescent girl. Indian J Paediatr Dermatol 2019;21:70-2.
Introduction
Vitiligo and psoriasis are common skin disorders, and their coexistence is frequently seen. However, anatomical colocalization of vitiligo and psoriasis is a rarity. [1] This colocalization can be a mere coincidence or the result of a common etiopathogenetic pathway. Several genetic and environmental factors such as the Koebner phenomenon are involved in the development of these diseases. [2, 3] Simultaneous treatment of both the conditions is a therapeutic challenge. Several therapeutic modalities have been tried such as topical steroids, tacrolimus, ultraviolet B (UVB) phototherapy, and etanercept with varying results. Apremilast is a PDE4 inhibitor, recently approved by the US Food and Drug Administration for the treatment of psoriasis. A study also demonstrated repigmentation of tenacious vitiligo with apremilast. [4] It can also be safely combined with narrowband (NB) UVB therapy to increase the therapeutic efficacy. [5] Although clinical trials are absent in the pediatric population, an isolated case report has documented the efficacy and safety of apremilast in an adolescent boy with psoriasis at the adult dosage (30 mg twice daily). [6] Here, we report a case of anatomical colocalization of vitiligo and psoriasis successfully treated with apremilast and NB-UVB therapy in a pediatric patient.
Case Report
A 13-year-old girl presented with gradually progressive depigmented patches over the face, scalp, trunk, and bilateral limbs for the past 6 months. Four months later, she developed scaly, hyperkeratotic plaques exactly over the depigmented patches [ Figure 1 ]. Clinical examination was suggestive of psoriasis plaques over vitiligo patches. Routine biochemistry including thyroid status and autoimmune screening was within the normal limits. Family history and drug history were unremarkable. The patient was administered NB-UVB (300 mJ/cm 2 ) with a 20% increment twice weekly and oral apremilast 30 g twice daily for 12 weeks. Psoriasis Area Severity Index (PASI) 75 was achieved at week 12 with a significant improvement in the Dermatology Life Quality Index. More than 50% repigmentation of the vitiligo patches was observed [ Figure 2 ]. The drug was well tolerated without any adverse effects. After week 12, NB-UVB therapy was discontinued, and apremilast is being continued with appreciable results.
Discussion
Vitiligo is a common disorder characterized by acquired development of depigmented Received: 09-08-2019 Accepted: 21-09-2019 Published: 24-12-2019 macules on the skin due to the loss of functioning melanocytes in the skin, the hair, or both. Although the pathogenesis is not known, it is presumed to be a cumulative effect of various mechanisms, including autoimmune, neurohormonal, genetic, oxidative stress, and cytotoxic damage. Psoriasis is linked to a dysregulated immune system caused by a pro-inflammatory cytokine network.
Both these diseases have common pathogenesis, i.e., tumor necrosis factor-alpha (TNF-α) pathway. Kovacs demonstrated enhanced levels of neurotensin-induced TNF-α production from the melanocytes in vitiligo lesions. [7] Jain et al. found an elevated level of TNF-α in the perilesional skin of patients with vitiligo. [8] Furthermore, TNF-α is known to be one of the key cytokines in the pathogenesis of psoriasis, and the level of TNF-α is elevated in psoriatic lesions.
There has been a single case report of colocalization of vitiligo and psoriasis in a pediatric patient by Dhar et al. in the Indian literature who concluded that there could be structural similarities between anti-stratum corneum antibodies and anti-melanocyte antibodies and also a common neuropeptide might be responsible for cohabitation of vitiligo and psoriasis. [9] Bakar-Dertlioğlu et al. reported three such cases in the Turkish population. [10] Apremilast induces an activation of the cyclic AMP (cAMP) pathway, leading to anti-inflammatory effect by decreasing the response of T-helper 1 (Th1) and Th17 lymphocytes. It causes the regulation of inflammatory mediators through the cAMP second messenger effect, for example, decreased expression of TNF-α, interleukin (IL)-17 and IL-23, interferon-gamma, as well as increased IL-10. The cAMP pathway is also well demonstrated to be the main pathway for promoting melanogenesis and for inducing the differentiation and the proliferation of melanocytes. [4, 5] A study by Bagel et al. showed that 73% of patients with chronic plaque psoriasis achieved PASI 75 in 12 weeks with apremilast and NB-UVB combination. [5] There is an ongoing placebo-controlled trial to assess the safety and efficacy of apremilast and NB-UVB in vitiligo.
Common side effects of apremilast are diarrhea, headache, nausea, vomiting, weight loss, and depression; these adverse events typically present early and are self-limiting. The advantages of using apremilast in the pediatric age group include ease of oral administration, minimal drug interaction potential, least monitoring, and safety.
A case report suggested that oral apremilast at adult dose of 30 mg twice daily was found to be effective, well-tolerated treatment option for adolescent patients with psoriasis; hence, we gave full dose of apremilast. Although our patient did not have any adverse events, clinical trial data are necessary to fully understand the safety and efficacy of apremilast in these patients.
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